WATERTOWN, Mass., April  23, 2026  (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (&#34;Tectonic&#34;), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and

TECX

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Strengthens Board with Healthcare Investment Banking Veteran

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>WATERTOWN, Mass., April  23, 2026  (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (&amp;#34;Tectonic&amp;#34;), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Tectonic Therapeutic has appointed Jessica Chutter to its Board, effective June 8, 2026. Her extensive investment banking background in biotech is expected to aid Tectonic&#039;s strategic direction and help in achieving growth as it develops multiple clinical programs.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Tectonic appointed Jessica Chutter to Board of Directors, effective June 8, 2026.</li><li>Chutter brings 40+ years of healthcare investment banking experience.</li><li>She will support Tectonic’s growth and clinical development strategies.</li><li>Tectonic focuses on GPCR-targeted drug discovery in unmet medical needs.</li><li>The company is advancing towards a multi-product clinical company.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Morgan Stanley (MS)</strong>: Chutter&#039;s prior experience at Morgan Stanley bolsters credibility.</li><li><strong>PTC Therapeutics (PTCT)</strong>: Chutter currently serves on their board, potentially enhancing collaboration opportunities.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The appointment of Jessica Chutter fits within Corporate Developments, emphasizing strategic governance in Tectonic&#039;s journey towards commercialization.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Investor confidence may rise due to Chutter&#039;s high-profile industry background.</li><li>Her expertise could facilitate strategic funding breakthroughs for Tectonic&#039;s R&amp;D activities.</li><li>Market response could be positive if Tectonic shares plans leveraging Chutter&#039;s network.</li><li>Potential partnerships may arise from her connections, enhancing growth prospects.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Jessica Chutter joins Tectonic&#039;s Board on June 8, 2026.</li><li>She has over $80 billion in capital raising experience.</li><li>Tectonic focuses on GPCRs with a specialized technology platform.</li><li>Tectonic seeks to address unmet medical needs in therapeutic areas.</li><li>Chutter has a strong track record in biotechnology investment banking.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying TECX shares in anticipation of positive growth trajectories.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>WATERTOWN, Mass., April  23, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=n7LKpo2UyblQRcviyW5xfobgjvXkK2xt14RvVLVHv5wE8EnhZnxlf4vYrvVqleC8FotYgEqPD7XQwYFRcWg9lIfl3UF81vP7P4kQGIyv48c=" rel="nofollow" target="_blank">Tectonic Therapeutic, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TECX">TECX</a>) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026.</p>  <p>Ms. Chutter brings more than four decades of experience in global healthcare investment banking, with deep expertise advising biotechnology and pharmaceutical companies on strategic positioning, mergers and acquisitions, and capital markets execution. She is widely recognized as a pioneer in investment banking in the biotechnology sector and has served as a trusted advisor to CEOs and boards across the industry.</p>  <p>"We are delighted to welcome Jessica to Tectonic's Board," said Dr. Alise Reicin, President and Chief Executive Officer of Tectonic Therapeutic. "Her deep, specialized knowledge in capital markets and strategic transactions will be instrumental as we execute on our priorities and position the company for sustained growth and long-term value creation. We look forward to her contributions as we advance into a multi-product clinical company."</p>  <p>Ms. Chutter spent her career at Morgan Stanley, where she served as Managing Director from 1998 to February 2026 and helped build its biotechnology investment banking practice. Most recently, she was Vice Chair of Healthcare Investment Banking from 2020 to February 2026 and Chair of Biotechnology Investment Banking from 2010 to February 2026. Earlier in her tenure, she served as Co-Head of Biotechnology Investment Banking and held various roles in healthcare investment banking. Over the course of her career, Ms. Chutter advised biotechnology and pharmaceutical companies on strategic and capital markets initiatives and was involved in approximately $80 billion in capital raising transactions and $85 billion in strategic transactions.</p>  <p>"I'm thrilled to join Tectonic's Board at this stage in the company's evolution," said Ms. Chutter. "The team has built a compelling platform and pipeline with two clinical programs targeting three indications and a maturing preclinical portfolio. The combination of strong science, experienced drug developers and differentiated clinical therapies positions Tectonic well for the future. I look forward to supporting the company's efforts to translate its exciting drug candidates and capabilities into meaningful outcomes for patients and shareholders."</p>  <p>Ms. Chutter currently serves on the Board of Directors of PTC Therapeutics. She is also on the Board of The Hospital for Sick Children and the Toronto Innovation Acceleration Partners, a not-for-profit organization focused on translating health science research into commercial opportunities. She holds an M.B.A. from Harvard Business School and a Bachelor of Arts in Commerce and Honors Economics from McGill University.</p>  <p><strong>About Tectonic</strong><br></br><a href="https://www.globenewswire.com/Tracker?data=n7LKpo2UyblQRcviyW5xfq7V58WFdY4uEe2SZtzpf9h7ZAwfrxi7aZgV0TkYrw-VI0Gq0VKqsqQ_BuidCTA1fUJCqGC4RpaAPv7kIFn64kU=" rel="nofollow" target="_blank">Tectonic Therapeutic</a> is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe&#x2122; (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=WMxsFk8q4HbKVQSvcqOjIr7pmwmR5vVkDe1pO256MBrU0qm-ICUz5mqd8UZmOTJZpTQF3m19F16K_RDrPy5BqplB7MxOmUYcoLf7kvhAVYo=" rel="nofollow" target="_blank">www.tectonictx.com</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=8_BnGg9GcTQ69ApJ-FUgmryT0mnKq-JtpgDsOVPs83rhHi9OxujTJNWtZ0ZYyq-NhQmKNiZnjPQ8I_mQiV7ultcQ7zJf8fPBArulI-98VR0=" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Forward-Looking Statements</strong><br></br>This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: expected changes in the membership of the board of directors and the benefits associated therewith. These forward-looking statements are based on Tectonic's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Tectonic's actual results to differ from those expressed or implied in the forward-looking statements in this press release. These risks and uncertainties include those that are identified under the heading "Risk Factors" in Tectonic's annual report on Form 10-K filed with the SEC on February 26, 2026, and in other filings that Tectonic makes and will make with the SEC in the future. Tectonic expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=WMxsFk8q4HbKVQSvcqOjIn-Wm9u6s1S1RN2V7q-9hnDvCy2DKROkgbmip6xMsRkVKD9zOFsGlmijdKqXi5jSahh-83ClcoD5itexdn0jA6sPIoAcpfH66cjBL_Wmt_H4frys4ur3DSYqGRfEEux1RIB_hBpZTL27cbK8lS8mKk4jLqqfy9ZQtQZaOiaiXbM6_zIdExw8ZjBFmncDipFfq6u6gCyhqlP1TYB6OZvlqmBvp9G6ojyjHEuViN7oBXYu4QSt2U0CLK3ZCtoluV8g9QFo9uUysmIMk3lrCVxssPDE4R6CvZoaoNTgfeByGv2NhDX5coujc6qFPAW6x8lXSUjZzR-_97UMAMkPXUsNpzaXv3meYHz4SZNWMJDAQlBTP1SIacj5j9VnBgJtbUXf_QQJsL4n07XYM0qo2r6Arg5IkN9RGRL835zfgQp7-G9RrrOIBXZdHJJT-HRodDdJsp2cwoy81aBXlrDJwzlI31M=" rel="nofollow" target="_blank">www.tectonictx.com</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=8_BnGg9GcTQ69ApJ-FUgmgdGHpF3_TBAltg-KdAtX5EsiAPqlBtNmPE-cOQpxscOpcR0L3_11xtY0kBFAqiE54eng9oH0W0NRkFw8ZHKbzA=" rel="nofollow" target="_blank">LinkedIn</a>.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5NjAyMyM3NTUzMDg0IzIxMDAxNTc="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YjllMThiMGEtYjFkZi00MTRhLTk1NDEtMGRmOThkMTMwMWVlLTExMTE3MjgtMjAyNi0wNC0yMy1lbg==/tiny/Tectonic-Therapeutic.png" referrerpolicy="no-referrer-when-downgrade"></img><pre>Contacts:

Investors:
Dan Ferry
LifeSci Advisors
<a href="mailto:daniel@lifesciadvisors.com">daniel@lifesciadvisors.com</a>
(617) 430-7576

Media:
Kathryn Morris
The Yates Network
<a href="mailto:kathryn@theyatesnetwork.com">kathryn@theyatesnetwork.com</a>
(914) 204-6412</pre><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/7c13d2a1-2971-4ab0-a4b5-608923316546"><img src="https://ml.globenewswire.com/media/7c13d2a1-2971-4ab0-a4b5-608923316546/small/tectonic-logo-full-color-png.png" border="0" width="150" height="41" alt="Primary Logo"></img></a></p>

Tectonic Therapeutic has appointed Jessica Chutter to its Board, effective June 8, 2026. Her extensive investment banking background in biotech is expected to aid Tectonic's strategic direction and help in achieving growth as it develops multiple clinical programs.

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News